Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: Results from 7 years of resistance surveillance (2003-2009)

Journal of Chemotherapy

Volumn 23, Issue 4, 2011, Pages 200-206

  Sader, H S ^a,b   Farrell, D J ^a   Jones, R N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Daptomycin; Europe; Resistance; Surveillance

Indexed keywords

DAPTOMYCIN; LINEZOLID; OXACILLIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BLOODSTREAM INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; EUROPE; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; ISRAEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS BOVIS; TURKEY (REPUBLIC); VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 80052692062     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.4.200     Document Type: Article

References (15)

1. EARSS (2009). European Antimicrobial Resistance Surveillance System. Available at http://www.rivm.nl/earss/. Accessed March 21, 2011.
2. ECDC (2009). Antimicrobial resistance surveillance in Europe. Avail able at http://www.ecdc.europa.eu. Accessed March 21, 2011.
3. Jones RN, Sader HS, Moet GJ, Farrell DJ. Declining antimicrobial sus ceptibility of Streptococcus pneumoniae in the United States: Report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn Mi crobiol Infect Dis. 2010; 68: 334-336.
4. WHO global strategy for containment of antimicrobial resistance. Geneva: World Health Organization; 2001.
5. Eisenstein BI, Oleson FB, Jr, Baltz RH. Daptomycin: From the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis. 2010; 50 Suppl 1: S10-S15.
6. Cubicin. Lexington, (MA): Cubist Pharmaceuticals, Inc; 2009. Sakoulas. Clinical outcomes with daptomycin: A post-marketing, real-world evaluation. Clin Microbiol Infect. 2009; 15 Suppl 6: 11-16.
7. CLSI. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: Eighth edition Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
8. EUCAST (2011). Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, March 2011. Available at http://www.eucast.org/clinical_breakpoints/. Accessed March 18, 2011.
9. CLSI. M100-S21. Performance standards for antimicrobial suscepti bility testing: 21st informational supplmeent. Wayne, PA: Clinical and Lab oratory Standards Institute; 2011.
10. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus au reus in the antibiotic era. Nat Rev Microbiol. 2009; 7: 629-41.
11. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. 2008; 13: 19046.
12. Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: What is the evidence? J An-timicrob Chemother. 2010; 65: 1126-36.
13. Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospec tive, multicenter, cohort study. ClinTher. 2010; 32: 1713-1739.
14. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin non- susceptible enterococci: An emerging challenge for clinicians. Clin Infect Dis. 2011; 52: 228-34.
15. Raad I, Hachem R, Hanna H, Afif C, Escalante C, Kantarjian H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium in fections. J Antimicrob Chemother. 2004; 53: 646-649.